ArticleBiological trace element research2026
From Antibacterial to Antifungal: Structure, Safety, and Serum Albumin Binding of Zn(II)-Nalidixate Complexes with Phenanthroline and Bipyridine.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nalidixic acid (Nal) is a quinolone antibiotic with activity against Gram-negative bacteria and is used to treat urinary tract infections caused by microorganisms belonging to the genera Escherichia, Proteus, Shigella, Enterobacter, and Klebsiella. The complexation of this molecule with zinc and auxiliary ligands such as phenanthroline (Phen) and 2,2'-bipyridine (Bipy) could modify its pharmacological and pharmacokinetic properties. This work presents the synthesis and characterization of the ZnNal complex ([Zn(Nal)₂(H₂O)₂]·2MeOH). Its molecular structure in the solid state was determined by X-ray diffraction. The complex crystallizes in the monoclinic space group P2₁/n with Z = 2 molecules per unit cell. In the solid state, the nalidixic acid (Nal) molecule appears as its anionic form (Nal⁻), deprotonated in the carboxyl group. The complex is centrosymmetric, with the Zn(II) ion at the center of a slightly elongated octahedral geometry, equatorially coordinated to a bidentate nalidixate anion and axially to a water molecule. The study includes the evaluation of antimicrobial activity of the binary complex and its derivatives with phenanthroline (ZnNalPhen) and bipyridine (ZnNalBipy) against both ATCC strains and clinical isolates. Additionally, compound safety was assessed using the Artemia salina model. ZnNal preserves the antimicrobial potency of the free ligand while exhibiting attenuated toxicity in this model, suggesting a more favorable biocompatibility profile for potential therapeutic applications. Notably, ZnNalPhen was the only complex active against Candida strains, highlighting that coordination with 1,10-phenanthroline expanded the antimicrobial spectrum of the parent ligand Nal to include antifungal activity. Furthermore, both ternary complexes showed an improved safety profile compared to Nal alone. Besides, zinc(II) complexes can be efficiently transported by albumin, which is a key factor in their potential therapeutic application.
Indexed as
Identifiers
42584833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.